Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

NCT01265745 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Anthrax

Interventions

DRUG: Normal Saline for Injection
BIOLOGICAL: MDX1303

Sponsor

PharmAthene, Inc.

Collaborators

[object Object]
[object Object]
[object Object]